Open AccessCutting-edge biotechnological advancement in islet delivery using pancreatic and cellular approaches
Author(s) -
Magdy M. M. Elnashar,
Mauro Vaccarezza,
Hani AlSalami
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2020-0105
Subject(s) - islet , immunosuppression , economic shortage , transplantation , pancreas , insulin delivery , regenerative medicine , medicine , pancreatic islets , insulin , cell encapsulation , type 1 diabetes , biology , stem cell , diabetes mellitus , endocrinology , cell , microbiology and biotechnology , biochemistry , linguistics , philosophy , government (linguistics)
There are approximately 1 billion prediabetic people worldwide, and the global cost for diabetes mellitus (DM) is estimated to be $825 billion. In regard to Type 1 DM, transplanting a whole pancreas or its islets has gained the attention of researchers in the last few decades. Recent studies showed that islet transplantation (ILT) containing insulin-producing β cells is the most notable advancement cure for Type 1 DM. However, this procedure has been hindered by shortage and lack of sufficient islet donors and the need for long-term immunosuppression of any potential graft rejection. The strategy of encapsulation may avoid the rejection of stem-cell-derived allogeneic islets or xenogeneic islets. This review article describes various biotechnology features in encapsulation-of-islet-cell therapy for humans, including the use of bile acids.